Andere talen Valeo Pharma Inc. Canadian Securities Exchange

Aandelen

VPH

CA91915B1085

Vertraagde tijd Canadian Securities Exchange Andere beurzen 21:57:37 28-03-2022			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,66 ^CAD	-.--%		+1,54%	-10,81%

25/04	Transcript : Valeo Pharma Inc. - Shareholder/Analyst Call
22/03	Valeo Pharma Inc. kondigt de benoeming aan van Al Moghaddam tot lid van de Raad van Bestuur	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

VALEO PHARMA ANNOUNCES RESULTS OF ANNUAL MEETING OF SHAREHOLDERS	25/04
VALEO PHARMA TO PRESENT AT THE 2024 BLOOM BURTON & CO HEALTHCARE INVESTOR CONFERENCE	09/04
VALEO PHARMA ANNOUNCES APPOINTMENT OF MR. AL MOGHADDAM TO BOARD OF DIRECTORS	25/03
VALEO PHARMA ANNOUNCES APPOINTMENT OF MR. AL MOGHADDAM TO BOARD OF DIRECTORS	22/03
Valeo Pharma Inc. Announces Appointment of Al Moghaddam to Board of Directors	22/03
VALEO PHARMA REPORTS FIRST QUARTER 2024 RESULTS	14/03
Valeo Pharma Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024	14/03
VALEO PHARMA TO HOST FIRST QUARTER 2024 RESULTS CONFERENCE CALL, WEBCAST	08/03
VALEO PHARMA TO HOST FIRST QUARTER 2024 RESULTS CONFERENCE CALL / WEBCAST	07/03
VALEO PHARMA ANNOUNCES BOARD OF DIRECTORS CHANGES	13/02
Valeo Pharma Inc. Announces Board Changes	13/02
Valeo Pharma Brief: Notes Sagard credit facility amended to provide for early repayments and liquidity requirements in fiscal 2024	02/02
Valeo Pharma Brief: Says Proceeds from reimbursement to be used for debt reduction purposes	02/02
Valeo Pharma Brief: Adding SIMBRINZA remains under Valeo Pharma exclusive promotion and distribution	02/02
Valeo Pharma Brief: Says Original commercialization and supply agreement amended following global divestment of XIIDRA	02/02
Valeo Pharma Brief: Amending Agreement With Novartis Pharmaceuticals Canada For XIIDRA In Canada, and Credit Facility With Sagard Healthcare Royalty Partners, LP	02/02
VALEO PHARMA AMENDS AGREEMENT WITH NOVARTIS PHARMACEUTICALS CANADA FOR (Pr)XIIDRA® IN CANADA AND CREDIT FACILITY WITH SAGARD HEALTHCARE ROYALTY PARTNERS, LP	02/02
Valeo Pharma Amends Agreement with Novartis Pharmaceuticals Canada for (Pr)XIIDRA in Canada	02/02
Valeo Pharma Inc. Amends Credit Facility with Sagard Healthcare Partners, LP	02/02
Valeo Pharma's Q4'23 Net Loss Holds Steady YOY	30/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Valeo Pharma Inc. Canadian Securities Exchange

Aandelen

VPH

CA91915B1085

Andere talen

Filters